Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Iovance Biotherapeutics, Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Southern California
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University Health Network, Toronto
HiFiBiO Therapeutics
Seattle Children's Hospital
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
Valo Therapeutics Oy
Sensei Biotherapeutics, Inc.
Ascentage Pharma Group Inc.
Roswell Park Cancer Institute
OncoC4, Inc.
SOLTI Breast Cancer Research Group
Immunophotonics, Inc.
Adaptimmune